Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. TOT BIOPHARM International Company Limited
  6. News
  7. Summary
    1875   HK0000545266

TOT BIOPHARM INTERNATIONAL COMPANY LIMITED

(1875)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

TOT BIOPHARM International Company Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2021

08/12/2021 | 10:53am EST

TOT BIOPHARM International Company Limited reported unaudited consolidated earnings results for the six months ended June 30, 2021. For the period the company reported revenue of RMB 23,132,000 against RMB 13,030,000 a year ago. Operating loss was RMB 115,445,000 against RMB 128,363,000 a year ago. Loss for the period and attributable to the equity holders of the Company was RMB 115,005,000 or RMB 0.2 per basic and diluted share against RMB 129,183,000 or RMB 0.23 per basic and diluted share a year ago.


ę S&P Capital IQ 2021
All news about TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
01/12TOT Biopharm International Unit Grants Kexing License to Commercialize Cancer Drug Over..
MT
01/03TOT Biopharm Arm Engages MCC Unit to Construct Global R&D Center in Chinese Province
MT
2021TOT Biopharm Sells 1 Million Shares in Lumosa Therapeutics to Center Laboratories
MT
2021TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin« (TAB008, Bevacizum..
PR
2021TOT BIOPHARM International Company Limited Announces NMPA Granted Marketing Approval fo..
CI
2021TOT Biopharm's Lung Cance Drug Bags Marketing Approval in China; Shares Rally 5%
MT
2021TOT Biopharm International Forms Pharma Sales JV With China Resources Pharmaceutical
MT
2021TOT Biopharm Narrows Loss in January-September as Revenue Doubles; Shares Rally 4%
MT
2021TOT BIOPHARM International Company Limited Reports Unaudited Consolidated Earnings Resu..
CI
2021TOT BIOPHARM INTERNATIONAL : 2021 Interim Revenue Surges 78% to RMB23.13 million
AQ
More news
Financials
Sales 2021 95,9 M 15,1 M 15,1 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 2 510 M 322 M 395 M
Capi. / Sales 2021 26,2x
Capi. / Sales 2022 8,64x
Nbr of Employees 354
Free-Float -
Chart TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
Duration : Period :
TOT BIOPHARM International Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 4,08 CNY
Average target price 5,70 CNY
Spread / Average Target 39,6%
Managers and Directors
Jun Liu CEO, Executive Director & Chief Scientific Officer
Shan Fu Non-Executive Chairman
Ming Liu Chief Medical Officer & Vice General Manager
Lan Hu Independent Non-Executive Director
Lijun Sun Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
TOT BIOPHARM INTERNATIONAL COMPANY LIMITED-4.45%324
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%53 950
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684